1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.

TRVI
Trevi Therapeutics, Inc.US flagNASDAQ Global Market
13.45
USD
-0.05
- -
1.91BMarket Cap

Total Valuation

Trevi Therapeutics, Inc. carries a market capitalization of 1.91B, placing it among publicly traded companies globally. Its enterprise value stands at 1.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.91B
Enterprise Value1.52B

Share Statistics

Trevi Therapeutics, Inc. currently has 128.41M shares outstanding.

Shares Outstanding128.41M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio-4.93
P/TBV Ratio9.82
P/FCF Ratio-37.39
P/OCF Ratio-37.30

Financial Position

Trevi Therapeutics, Inc. maintains a current ratio of 24.75, meaning it holds 24.8x the short-term assets needed to cover near-term liabilities.

Current Ratio24.75
Quick Ratio24.14
Debt / Equity0.40
Debt / EBITDA-0.01
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-31.83
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax-72,000.00
Effective Tax RateN/A

Stock Price Statistics

Trevi Therapeutics, Inc.'s stock has gained approximately 104.40729% over the past 52 weeks. The 50-day moving average sits at 13.64, while the 200-day moving average is 11.41.

Beta (5Y)N/A
52-Week Price Change104.40729%
50-Day Moving Average13.64
200-Day Moving Average11.41
Average Volume (20 Days)N/A

Income Statement

EBITDA reached -52.63M, while operating income came in at -52.77M.

RevenueN/A
Gross ProfitN/A
Operating Income-52.77M
Pretax Income-45.68M
Net Income-45.61M
EBITDA-52.63M
EBIT-52.77M
Earnings Per Share (EPS)-0.32

Balance Sheet

Trevi Therapeutics, Inc. holds 171.78M in cash and equivalents against 682,000.00 in total debt, resulting in a net debt position of -19.41M. Total book value stands at -342.87M, with working capital of 169.01M providing operational flexibility.

Cash & Cash Equivalents171.78M
Total Debt682,000.00
Net Debt-19.41M
Equity (Book Value)-342.87M
Book Value Per Share-2.42
Working Capital169.01M

Cash Flow

Trevi Therapeutics, Inc. produced -45.30M in operating cash flow over the past twelve months. After subtracting -114,000.00 in capital expenditures, free cash flow totaled -45.41M - equivalent to -0.32 per share.

Operating Cash Flow-45.30M
Capital Expenditures-114,000.00
Free Cash Flow-45.41M
FCF Per Share-0.32

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-6.66
FCF Yield-2.67

Scores

Trevi Therapeutics, Inc. posts an Altman Z-Score of 133.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score133.04